This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garrelts, J. C.
Right arrow Articles by Lettieri, J. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garrelts, J. C.
Right arrow Articles by Lettieri, J. T.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 1996, 1153-1156, Vol 40, No. 5
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Ciprofloxacin pharmacokinetics in burn patients

JC Garrelts, G Jost, SF Kowalsky, GJ Krol and JT Lettieri
Via Christi Regional Medical Center, University of Kansas, School of Medicine-Wichita, USA.

Many drugs exhibit altered pharmacokinetic parameters in burn patients. We prospectively evaluated the pharmacokinetics of ciprofloxacin in eight burn patients with active infections. Each patient received a 400- mg dose of ciprofloxacin intravenously (i.v.) every 8 h, with each dose infused over 1 h by using a rate control device. Blood samples for analysis of plasma ciprofloxacin concentrations, determined by high- performance liquid chromatography, were obtained immediately predose, at the end of the infusion, and 1, 2, 3, 4, 5, 6, and 7 h after the end of the infusion. Urine was collected from 0 to 2, 2 to 4, and 4 to 8 h following the same dose, and an aliquot was saved for determination of the ciprofloxacin concentration. Urine was also collected for 24 h prior to this dose for measurement of creatinine clearance (CLCR). Pharmacokinetic parameters were estimated by noncompartmental analysis. Mean maximum and minimum plasma ciprofloxacin concentrations were 4.2 +/- 1.1 and 0.70 +/- 0.55 microgram/ml, respectively. Mean values for clearance (CL), renal clearance (CLR), volume of distribution, terminal elimination rate constant, half-life (t1/2), and area under the concentration-time curve (AUC) were 29.1 +/- 17.5 liters/h, 13.5 +/- 10.1 liters/h, 1.75 +/- 0.41 liters/kg, 0.222 +/- 0.098 h-1, 4.5 +/- 3.9 h, and 20.7 +/- 16.6 micrograms.h/ml, respectively. CL was higher and t1/2 was shorter than noted in previous studies of acutely ill, hospitalized patients. A good correlation was noted between creatinine clearance CL(CR) and both total ciprofloxacin CL (r = 0.85) and CLR (r = 0.84). A moderate inverse correlation was noted between percent body surface area burned and total ciprofloxacin CL (r = -0.55). An AUC/MIC ratio above 125 SIT-1 (where SIT is serum inhibitory titer), which has been strongly correlated with clinical response and time to bacterial eradication, was achieved in five of eight patients (63%) with a MIC of 0.25 microgram/ml. At a ciprofloxacin dosage of 400 mg i.v. every 12 h, an AUC/MIC ratio above 125 SIT-1 would have been achieved in only two of eight patients (25%). We conclude that ciprofloxacin CL is highly variable, but generally increased, in burn patients compared with that in acutely ill, general medical and surgical patients. Because of an increase in CL, a ciprofloxacin dosage of 400 mg i.v. every 8 h is more likely to produce the desired response in burn patients than the same dose given every 12 h.


This article has been cited by other articles:

  • Tanigawara, Y., Sato, R., Morita, K., Kaku, M., Aikawa, N., Shimizu, K. (2006). Population Pharmacokinetics of Arbekacin in Patients Infected with Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 50: 3754-3762 [Abstract] [Full Text]  
  • Kiser, T. H., Hoody, D. W., Obritsch, M. D., Wegzyn, C. O., Bauling, P. C., Fish, D. N. (2006). Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury.. Antimicrob. Agents Chemother. 50: 1937-1945 [Abstract] [Full Text]  
  • Oldak, E., Trafny, E. A. (2005). Secretion of Proteases by Pseudomonas aeruginosa Biofilms Exposed to Ciprofloxacin. Antimicrob. Agents Chemother. 49: 3281-3288 [Abstract] [Full Text]  
  • Varela, J. E., Cohn, S. M., Brown, M., Ward, C. G., Namias, N., Spalding, P. B. (2000). Pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin in patients with major thermal injuries. J Antimicrob Chemother 45: 337-342 [Abstract] [Full Text]  
  • Weinbren, M. J. (1999). Pharmacokinetics of antibiotics in burn patients. J Antimicrob Chemother 44: 319-327 [Abstract] [Full Text]